Kiran Patel’s Post

On Pancreatic Cancer Day, we shed light on this challenging disease. Pancreatic cancer begins with cell changes that lead to the growth of abnormal tissue masses. Early detection is crucial for successful treatment. By raising awareness and promoting regular screenings, we can increase the chances of detecting it early and providing timely care. Together, we can make a difference in the fight against pancreatic cancer. 🎗️ #PancreaticCancerAwareness #EarlyDetection #HopeForACure

At Johnson & Johnson Innovative Medicine, we are committed to leading where medicine is going – and nowhere is this more evident than in our rapidly expanding #LungCancer pipeline and portfolio.    We have submitted our third application to the U.S. FDA in four months for the treatment of lung cancer. This application focuses on our targeted therapy combination for the first-line treatment of patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC).    This submission reinforces the potential of our targeted therapies to transform the standard of care for those with #NSCLC.   We will continue to pursue combination-based regimens that address the highest unmet needs in lung cancer. Learn more here: https://bit.ly/3GOkPtf   #MyCompany

According to American Cancer Society’s Cancer Facts & Figures 2023, pancreatic cancer has a 5-year combined overall survival rate of 12% (Stages I-IV) and is on track to be the second leading cause of cancer-related deaths before 2030. The RenovoRx mission is to transform the current standard of care for patients diagnosed with #pancreaticcancer. Our proprietary TAMP™ therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy’s toxicities versus systemic intravenous (IV) therapy. Phase III interim analysis data presented at ESMO GI 2023 showed a trend towards improved overall survival benefit and a noticeable reduction in adverse events versus the standard of care in #LocallyAdvancedPancreaticCancer. Learn more: https://bit.ly/3DbaAgR #PanCANAwareness #PancreaticCancerAwareness

One in every six deaths are caused by cancer globally. Today, we commemorate #WorldCancerDay to highlight the ongoing efforts in the medical sector to reduce cancer mortality. Axcelead's #drugdiscovery services contribute to the analysis of #cancer cells, as well as to evaluate drug responses leading to the development of treatments and cures for all types of cancers. We hope that our continuous oncological drug discovery services will lead to more remissions and positive outcomes in the future. Learn more about our #oncology related services here:　https://lnkd.in/g_6kbXNT

On November 16, 2023, the FDA approved Keytruda (pembrolizumab) with fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma. Keytruda Prescribing Information https://lnkd.in/eKUyKs-e The recommended pembrolizumab dose is 200 mg every 3 weeks or 400 mg every 6 weeks until disease progression or unacceptable toxicity. Pembrolizumab should be administered prior to chemotherapy when given on the same day. #Oncology #Cancer #Keytruda #pembrolizumab #GastricAdenocarcinoma #GastroEsophagealJunctionAdenocarcinoma #GEJAdenocarcinoma #HER2 #Moffitt #MoffittCancerCenter Moffitt Cancer Center

So, how prevalent is ecDNA in cancer? ecDNA are present in about 14% of cancer at diagnosis and up to 32% of advanced cancers, across multiple tumor types. That is one reason why Boundless is working tirelessly to bring transformative new medicines to patients with oncogene amplified cancer through ecDNA-directed therapies (ecDTx), making treatment more effective and offering new possibilities for patients to overcome this challenging disease. Learn more about the prevalence of ecDNA below. 

Lung cancer remains one of the most prevalent forms of Cancer worldwide, often diagnosed at a late stage when treatment options are more limited. This World Lung Cancer Day, by fostering a greater understanding of the disease and supporting efforts to combat it, we at COD aim to advance clinical research and drug development, and to emphasize the importance of early detection. To know more about us, write to us at bd@cod-research.com Designing Therapies for Future #WorldLungCancerDay2024 #WLCD24 #ClosetheCareGap #EveryoneDeservesAccesstoCancerCare #CODResearch

What is the future for breast cancer diagnostics?  🎥  In this short film we look at the evolving landscape, and  the increasing significance of diagnostics in our targeted approach to cancer treatment. As Professor John Bartlett puts it, 'Diagnostics are becoming much, much more important now as we start to target drugs against specific changes in cancer. Now we're getting to the actual tailoring of therapy.' Discover how MammaTyper® is revolutionizing patient identification for targeted drug therapy, offering not only cost savings but also life-saving benefits and advancements in cancer care. We want to pave the way for personalized medicine in the fight against breast cancer.  #BreastCancerAwareness #FutureOfMedicine #PersonalizedCare"

Heading to #ASCO24? Join Andrea Necchi, MD, Matthew Galsky, MD, Shilpa Gupta, MD, and Michiel S. van der Heijden, MD, PhD on Friday, May 31 at 6:30 PM CDT / 7:30 PM EDT in person or online for a Candid Conversations on Urothelial Cancer #MedEd event. Produced with the Bladder Cancer Advocacy Network, This event will provide insight on how immune checkpoint inhibitors, fibroblast growth factor receptor (#FGFR) inhibitors, and antibody-drug conjugates (#ADCs), approved or being studied as monotherapy or in combination with other agents, along with novel approaches to drug delivery, can be used in patients with advanced or metastatic disease and increasingly in earlier stages of disease. 🔗 Register now: https://lnkd.in/e59Bmk3S #BladderCancer #Oncology #MedEd #ASCO24

According to American Cancer Society’s Cancer Facts & Figures 2023, pancreatic cancer has a 5-year combined overall survival rate of 12% (Stages I-IV) and is on track to be the second leading cause of cancer-related deaths before 2030. The RenovoRx mission is to transform the current standard of care for patients diagnosed with #pancreaticcancer. Our proprietary TAMP™ therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy’s toxicities versus systemic intravenous (IV) therapy. Phase III interim analysis data presented at ESMO GI 2023 showed a trend towards improved overall survival benefit and a noticeable reduction in adverse events versus the standard of care in #LocallyAdvancedPancreaticCancer. Learn more: https://bit.ly/3DbaAgR #PanCANAwareness #PancreaticCancerAwareness